Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells (Q34114810)

31 July 2017

title

Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells (English)

1 reference

31 July 2017

0 references

1 reference

Cao Yang

1

1 reference

31 July 2017

Edwin Choy

2

1 reference

31 July 2017

Francis J Hornicek

3

1 reference

31 July 2017

Kirkham B Wood

4

1 reference

31 July 2017

Joseph H Schwab

5

1 reference

31 July 2017

Xianzhe Liu

6

1 reference

31 July 2017

Henry Mankin

7

1 reference

31 July 2017

Zhenfeng Duan

8

1 reference

31 July 2017

publication date

12 May 2010

1 reference

Cancer Chemotherapy and Pharmacology

31 July 2017

published in

1 reference

31 July 2017

volume

67

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

439-446

1 reference

HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1344-7

The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1344-7

Radiosensitization by the histone deacetylase inhibitor PCI-24781.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1344-7

Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1344-7

CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1344-7

Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1344-7

Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1344-7

Clinical development of histone deacetylase inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1344-7

Acetylation and deacetylation of non-histone proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1344-7

Activities of human recombination protein Rad51.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1344-7

Mechanisms of sarcoma development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1344-7

21 January 2018

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1344-7

GADD45A is a mediator of CD437 induced apoptosis in ovarian carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1344-7

Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1344-7

Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of Clusterin/Apolipoprotein J.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1344-7

Challenges and complexities in estimating both the functional impact and the disease risk associated with the extensive genetic variation in human DNA repair genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1344-7

BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1344-7

Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1344-7

RAD51, genomic stability, and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1344-7

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1344-7

Functions of site-specific histone acetylation and deacetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1344-7

Ecteinascidin-743 drug resistance in sarcoma cells: transcriptional and cellular alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1344-7

Histone deacetylase inhibitors: anticancer compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1344-7

Molecular targets in therapy for human soft-tissue and bone sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1344-7

Acetylation of histones and transcription-related factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1344-7

Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1344-7

Multidrug resistant osteosarcoma cell lines exhibit deficiency of GADD45alpha expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1344-7

Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1344-7

10.1007/S00280-010-1344-7

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1028293907

0 references

1 reference